Stockholm Stock Exchange | Mid Cap
3 months
RBCRX SecuritiesCarnegieDNB Markets

Price Targets For Bioarctic

AnalystPrice TargetDateUpside
RBC230 SEKMay 10
RX Securities205 SEKApr 20
Carnegie225 SEKOct -21
DNB Markets250 SEKJul -21

About The Company

BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression.